1.	GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 114267, NCT01245062
2.	A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 115306, NCT01584648
3.	Study to Determine the Effectiveness of GSK1120212 in BRAF Mutation-positive Melanoma Previously Treated With or Without a BRAF Inhibitor Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 113583, NCT01037127
4.	Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212 Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 113220, NCT01072175
5.	Study of GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Metastatic Pancreatic Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 113487, NCT01231581
6.	An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 114653, NCT01362296
7.	Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Temporarily closed Age: 18 and over Sponsor: Other Protocol IDs: OSU-12064, NCI-2012-01700, NCCNGSK20014, NCT01723202
8.	Open-label Study to Investigate the Safety, PK, and Pharmacodynamics of GSK1120212 in Subjects With Solid Tumors or Lymphoma Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: MEK111054, NCT00687622
9.	A Study of the GSK MEK Inhibitor GSK1120212 and Everolimus in Cancer Subjects Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 112110, NCT00955773
10.	Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 113486, 2012-000257-32, NCT01192165
11.	Trial of GSK1120212 and GSK1120212 in Combination With GEM in Japanese Subjects With Solid Tumors Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 20 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 114784, NCT01324258
12.	GSK1120212 Food-effect Study Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 113709, NCT01371487
13.	Study to Investigate the Absorption, Distribution, Metabolism and Elimination of [14C]GSK1120212 Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 113708, NCT01387204
14.	Absolute Bioavialability of GSK1120212 Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 115064, NCT01416337
15.	A Study of the Safety and Activity of the MEK Inhibitor Given Together With the AKT Inhibitor to Patients With Multiple Myeloma or Solid Tumor Cancers Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 115829, NCT01476137
16.	Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) Formulation Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 115892, NCT01647659
17.	Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 Phase: No phase specified Type: Biomarker/Laboratory analysis Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: LCCC 1122, 11-1689, NCT01467310